» Articles » PMID: 27098816

Current Approach to the Diagnosis and Management of Portopulmonary Hypertension

Overview
Specialty Gastroenterology
Date 2016 Apr 22
PMID 27098816
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Portopulmonary hypertension (POPH) is a form of pulmonary arterial hypertension occurring in the setting of portal hypertension with or without hepatic cirrhosis. The presence of both portal and pulmonary vascular disease contributes to complicated hemodynamics and therapeutic challenges, though the severities do not appear to correlate directly. Diagnosis of POPH, and distinction from the commonly observed hyperdynamic state of end-stage liver disease, is typically accomplished with an initial screening transthoracic echocardiogram, followed by right heart catheterization for confirmation of hemodynamic parameters. Though few studies have directly evaluated use in POPH, pulmonary artery-directed therapy is the cornerstone of management, along with consideration of liver transplantation. Perioperative and long-term outcomes are variable, but uniformly worse in the setting of uncontrolled pulmonary pressures. Risk stratification and optimal patient selection for these interventions are areas of ongoing investigation.

Citing Articles

Hepatopulmonary Syndrome: A Comprehensive Review.

Qasim A, Jyala A, Shrivastava S, Allena N, Ghazanfar H, Bhatt V Cureus. 2024; 16(7):e65204.

PMID: 39176346 PMC: 11340781. DOI: 10.7759/cureus.65204.


Gut Dysbiosis and Hemodynamic Changes as Links of the Pathogenesis of Complications of Cirrhosis.

Efremova I, Maslennikov R, Poluektova E, Zharkova M, Kudryavtseva A, Krasnov G Microorganisms. 2023; 11(9).

PMID: 37764046 PMC: 10537778. DOI: 10.3390/microorganisms11092202.


Hemodynamic and Clinical Response to Liver Transplantation in Children and Young Adults POPH Patients.

Baba S, Ogawa E, Akagi K, Matsuda K, Hirata T, Okamoto T Pediatr Cardiol. 2023; 45(5):1142-1150.

PMID: 36754885 DOI: 10.1007/s00246-023-03121-0.


Assessment of biventricular function in patients with hepatopulmonary syndrome.

Soulaidopoulos S, Vlachou M, Cholongitas E, Giannakoulas G, Panagiotidis T, Drakopoulou M Int J Cardiovasc Imaging. 2021; 37(10):2891-2900.

PMID: 34114149 DOI: 10.1007/s10554-021-02260-w.


Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis.

You H, Peng L, Zhao J, Fei Y, Wang Q, Zhang W J Immunol Res. 2020; 2020:2156762.

PMID: 32537465 PMC: 7260626. DOI: 10.1155/2020/2156762.


References
1.
Awdish R, Cajigas H . Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience. Lung. 2013; 191(6):593-600. DOI: 10.1007/s00408-013-9501-5. View

2.
Lee S, Shroyer K, Markham N, Cool C, Voelkel N, Tuder R . Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998; 101(5):927-34. PMC: 508641. DOI: 10.1172/JCI1910. View

3.
Olschewski H, Rose F, Schermuly R, Ghofrani H, Enke B, Olschewski A . Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004; 102(2):139-53. DOI: 10.1016/j.pharmthera.2004.01.003. View

4.
Krowka M, Mandell M, Ramsay M, Kawut S, Fallon M, Manzarbeitia C . Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl. 2004; 10(2):174-82. DOI: 10.1002/lt.20016. View

5.
Rodriguez-Roisin R, Krowka M, Herve P, Fallon M . Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004; 24(5):861-80. DOI: 10.1183/09031936.04.00010904. View